Russian govt to allocate $840 million for high-priced drugs in 2022

7 December 2021
russia_duma_big

The Russian government will allocate about 62 billion roubles ($840 million) in 2022 for the procurements of high-priced drugs as part of the 14 high-cost nosologies (14 VZN) program, a state program, which involves procurements of the most expensive drugs for state needs in Russia, reports The Pharma Letter’s local correspondent.

According to representatives of some leading patient organizations in Russia, while this volume is 3% higher than in 2021, it is almost 1.5 times less than required volume, which may create a risk a shortage of some drugs in the local market.

According to a letter, which was recently prepared by the Russian Ministry of Health, the planned volume of drug purchases under the program will increase up to 1.55 billion packages in 2022, requiring about 61.8 billion roubles of funding.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical